Quantum Simulation Technologies (QSimulate), a Boston, MA-based quantum simulation technology company focused on drug discovery and other industry research and development, raised $2.5M in funding.
The round was led by 2xN. Other investors included UTokyo IPC and Kyoto iCAP.
The company intends to use the funds to support its business centered on its quantum physics-based drug-discovery platform, QSP Life.
Led by CEO QSimulate is a leader in quantum simulation technology for drug discovery and other industry research and development. The company offers a range of products and services designed to leverage quantum mechanics to solve industrial-scale problems. The quantum physics-based drug-discovery platform, QSP Life, currently includes QUELO, QuValent, and QuantumFP, spanning small-molecule lead optimization to covalent inhibitor design, and to ultra-high-throughput molecular fingerprinting.
In a multi-year partnership with Google Quantum AI, QSimulate has played a key role in the development of fault-tolerant quantum computing algorithms for chemical, material, and biomolecular problems. These contributions provide a roadmap for algorithm design in the quantum future supported by the existing QSimulate technologies. The ongoing collaborations with JSR Corporation and Google Quantum AI are a testament to its position in leveraging quantum mechanics for drug discovery and materials innovation, setting a new industry benchmark.
FinSMEs
29/11/2023